| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/25/2002 | WO2002032943A2 Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization |
| 04/25/2002 | WO2002032942A2 Compositions and methods for modulating rsv infection and immunity |
| 04/25/2002 | WO2002032936A2 E. histolytica-specific antibodies and clinical uses thereof |
| 04/25/2002 | WO2002032934A1 Antisense peptides to human fc receptors and their uses |
| 04/25/2002 | WO2002032923A2 Improved formulations using heat shock/stress protein-peptide complexes |
| 04/25/2002 | WO2002032455A2 Vaccine |
| 04/25/2002 | WO2002032454A1 Adjuvant composition comprising an immunostimulatory oligonucleotide and a tocol |
| 04/25/2002 | WO2002032453A1 Synthetic peptide hog cholera vaccine and method producing it |
| 04/25/2002 | WO2002032451A1 Vaccine composition comprising an antigen and a peptide having adjuvant properties |
| 04/25/2002 | WO2002032450A2 Vaccines |
| 04/25/2002 | WO2002032445A2 Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof |
| 04/25/2002 | WO2002032404A2 Nanoparticles |
| 04/25/2002 | WO2002032402A1 Composition and method for stable injectable liquids |
| 04/25/2002 | WO2002032378A2 Fusion cells and cytokine compositions for treatment of disease |
| 04/25/2002 | WO2001094387A3 Epididymis-specific proteins with fibronectin type ii modules |
| 04/25/2002 | WO2001088136A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 04/25/2002 | WO2001080897A3 Compositions and methods for in vivo delivery of polynucleotide-based therapeutics |
| 04/25/2002 | WO2001076617A3 Oral tolerance induction by collagen to prevent allograft rejection |
| 04/25/2002 | WO2001075072A3 Production of TcR gamma delta T cells |
| 04/25/2002 | WO2001072831A3 Immunoregulator |
| 04/25/2002 | WO2001072782A3 Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| 04/25/2002 | WO2001070262A3 A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of hiv envelope proteins |
| 04/25/2002 | WO2001068889A3 Method for gene transfection and vaccination through skin using electropermeabilization |
| 04/25/2002 | WO2001062300A3 Caspase activated prodrugs therapy |
| 04/25/2002 | WO2001060975A3 Gene disruption methodologies in fungi for drug target discovery |
| 04/25/2002 | WO2001060847A3 avirulent, immunogenic flavivirus chimeras |
| 04/25/2002 | WO2001058486A3 Immunomodulatory effective compositions, methods for the production thereof and their use |
| 04/25/2002 | WO2001054652A3 A method of inducing autovaccination against HIV infection using structured treatment interruptions |
| 04/25/2002 | WO2001042471A3 Polypeptides and polynucleotides encoding same |
| 04/25/2002 | WO2001041810A3 Nucleic acid delivery system |
| 04/25/2002 | WO2001029193A3 Cell constructs that are suitable for immunotherapy, the production and the use thereof |
| 04/25/2002 | US20020049495 Medical device with coating that promotes endothelial cell adherence |
| 04/25/2002 | US20020049404 Fas ligand expressing antigen presenting cells for tolerance induction |
| 04/25/2002 | US20020049314 Immunological adjuvant compounds compositions and methods of use thereof |
| 04/25/2002 | US20020049303 Enzymatic polypeptide for use as model for treatment of alzheimer's disease |
| 04/25/2002 | US20020049180 KIAA0175 inhibitor is selected from the group consisting of an anti-sense molecule, a ribozyme, an antibody, an antibody fragment, a protein, a polypeptide and a small molecule. |
| 04/25/2002 | US20020049177 Detecting an aberrant level or bioactivity of or screening for a Wnt pathway component or a frizzled related protein gene product |
| 04/25/2002 | US20020049151 Therapeutic approaches to diseases by suppression of the NURR subfamily of nuclear transcription factors |
| 04/25/2002 | US20020048816 Genetically engineered cell; for use as a vaccine; for use in screening polypeptides and antigens; for use as a support for immobilizing an enzyme, peptide or antigen |
| 04/25/2002 | US20020048790 Nucleotide sequences coding binding protein for use in the prevention of infections; bactericides |
| 04/25/2002 | US20020048786 Nucleotide sequences for use in the treatment of infections, arthritis, karposi's sarcoma, allergies, asthma, nervous system and autoimmune diseases |
| 04/25/2002 | US20020048784 Prostatic growth factor |
| 04/25/2002 | US20020048777 Nucleotide sequences for use in therapy, monitoring and screning preferential tumors |
| 04/25/2002 | US20020048590 Vaccine comprises a unit dose of an anthrax protective antigen and a specific antigen bound to an anthrax protective antigen binding protein. |
| 04/25/2002 | US20020048587 Containing an antigen or at least one in vivo generator of a compound comprising an amino acid sequence. |
| 04/25/2002 | US20020048586 Therapeutic compositions that alter the immune response |
| 04/25/2002 | US20020048584 Patients that are treated with HAART are then treated with an intensification regimen wherein hydroxyurea and didanosine (ddI) are given; followed by addition of compounds, such as OKT3 and IL-2, that activate latently infected cells |
| 04/25/2002 | US20020048583 Combining ex vivo an antigen and an antigen-presenting cell binding agent specific for the antigen, and administering the composition to a patient suffering from a disease associated with the antigen |
| 04/25/2002 | US20020048579 Treated tissue or organ can be transplanted in a recipient with reduced risk of graft-versus-host disease. |
| 04/25/2002 | US20020048578 Modified version of a therapeutic antibody with affinity for a cell-surface antigen; capable of inducing immunological tolerance to the therapeutic antibody |
| 04/25/2002 | US20020048564 Oligodeoxyribonucleotide having one or more NF- kappa B binding sites. |
| 04/25/2002 | US20020048562 Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance |
| 04/25/2002 | DE10045123A1 New transcription factor gene from Candida albicans, and its related polypeptide and antibody, useful for diagnosis and treatment of candida infection and for drug screening |
| 04/25/2002 | CA2689856A1 Composition and method for stable injectable liquids |
| 04/25/2002 | CA2463678A1 Assay for directly detecting a rs virus related biological cell in a body fluid sample |
| 04/25/2002 | CA2453140A1 Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof |
| 04/25/2002 | CA2426424A1 Haemophilus influenzae basb206 gene and protein |
| 04/25/2002 | CA2426413A1 Basb207 polypeptides and polynucleotides from nontypeable haemophilus influenzae |
| 04/25/2002 | CA2426366A1 Fusion cells and cytokine compositions for treatment of disease |
| 04/25/2002 | CA2426312A1 Compositions and methods for modulating rsv infection and immunity |
| 04/25/2002 | CA2425963A1 Human kinases |
| 04/25/2002 | CA2425727A1 Methods and compositions for promoting the maturation of monocytes |
| 04/25/2002 | CA2425669A1 Mutations in the ferroportin 1 gene associated with hereditary haemochromatosis |
| 04/25/2002 | CA2425362A1 Basb208 nucleotide and amino acid sequences from haemophilus influenzae |
| 04/25/2002 | CA2425310A1 Adjuvant composition comprising an immunostimulatory oligonucleotide and a tocol |
| 04/25/2002 | CA2422867A1 Improved formulations using heat shock/stress protein-peptide complexes |
| 04/24/2002 | EP1198568A1 Compositions and methods for the treatment of immune related diseases |
| 04/24/2002 | EP1198563A2 Novel fibroblast growth factor and nucleic acids encoding same |
| 04/24/2002 | EP1198560A2 Mammalian adhesion protease peptides |
| 04/24/2002 | EP1198479A1 Neovascular-targeted immunoconjugates |
| 04/24/2002 | EP1198468A1 Stabilized viral envelope proteins and uses thereof |
| 04/24/2002 | EP1198251A1 Combination of an anti-ep-cam antibody with a chemotherapeutic agent |
| 04/24/2002 | EP1198250A1 Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| 04/24/2002 | EP1198248A2 Immunotherapy in hiv infected persons using vaccines after multi-drug treatment |
| 04/24/2002 | EP1198246A2 Methods for preventing or attenuating pathoangiogenic conditions by using the gbs-toxin (cm101) receptor as a vaccine |
| 04/24/2002 | EP1198244A2 Strategy for carbohydrate-based cancer vaccines |
| 04/24/2002 | EP1198243A2 Use of cpg as an adjuvant for malaria vaccine |
| 04/24/2002 | EP1198240A2 Tissue regenerating agent |
| 04/24/2002 | EP0851768B1 Interactive molecular conjugates |
| 04/24/2002 | EP0752008B1 Dna mutagenesis by random fragmentation and reassembly |
| 04/24/2002 | EP0649537B1 Immunoassays for anti-hcv antibodies using antigens with conformational epitopes |
| 04/24/2002 | CN1346406A Human ubiquitin ligase E3 for the modulation of NF-kappa 8 |
| 04/24/2002 | CN1346372A Anti-idiotypic antibodies against antibodies which inhibit the binding of immunoglobuline to its high affinity receptor |
| 04/24/2002 | CN1346371A Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases |
| 04/24/2002 | CN1346370A Polypeptides involved in immune response |
| 04/24/2002 | CN1346367A HIV peptides, antigens, vaccine compositions, immunoassay kit and method of detecting |
| 04/24/2002 | CN1346290A Delivery of macromolecules into cells |
| 04/24/2002 | CN1346284A CD 40 binding molecules and CTL peptides for treating tumors |
| 04/24/2002 | CN1346282A Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as combination therapy method in treating neoplasia |
| 04/24/2002 | CN1346279A Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies |
| 04/24/2002 | CN1346276A Biodegradable and biocompatible polymeric microsphores encapsulating salmonella enteritidis bacteria |
| 04/24/2002 | CN1345775A Polypeptide for preventing, diagnosis and treating hepatitis E virus and used as diagnostic reagent and vaccine |
| 04/24/2002 | CN1345603A Composite disinfection live vaccin for rainbow virus or streptococcus infection and complication thereof of fishes |
| 04/24/2002 | CN1083279C Gel form of a vaccine and preparation process thereof |
| 04/23/2002 | US6376659 Recombinant expression vector |
| 04/23/2002 | US6376658 Used as therapeutics for malaria |
| 04/23/2002 | US6376657 Pharmaceutical compositions having appetite suppressant activity |
| 04/23/2002 | US6376654 Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof |
| 04/23/2002 | US6376653 Tie2 antagonist antibodies |
| 04/23/2002 | US6376651 Amino acid sequences of a caf 1-related protein and to the use of these sequences in the diagnosis, treatment, and prevention of disorders associated with cell proliferation and inflammation. |